UBS Group Lowers Insulet (NASDAQ:PODD) Price Target to $150.00

Insulet (NASDAQ:PODD) had its price objective cut by equities researchers at UBS Group from $174.00 to $150.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a “neutral” rating on the medical instruments supplier’s stock. UBS Group’s price target would indicate a potential upside of 8.56% from the company’s previous close.

PODD has been the subject of several other research reports. William Blair began coverage on Insulet in a research report on Wednesday, May 20th. They set an “outperform” rating for the company. Oppenheimer cut Insulet from an “outperform” rating to a “market perform” rating in a report on Wednesday. Royal Bank Of Canada reduced their target price on shares of Insulet from $245.00 to $160.00 and set an “outperform” rating on the stock in a research note on Thursday. Piper Sandler reduced their target price on shares of Insulet from $360.00 to $210.00 in a research note on Wednesday, May 6th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Insulet in a report on Tuesday, June 23rd. They issued a “buy” rating and a $190.00 target price on the stock. Fifteen investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $201.40.

Insulet Price Performance

NASDAQ PODD traded up $4.91 on Thursday, reaching $138.17. The company’s stock had a trading volume of 2,320,751 shares, compared to its average volume of 1,305,839. Insulet has a 52 week low of $126.40 and a 52 week high of $354.88. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. The firm has a market cap of $9.57 billion, a PE ratio of 32.14, a price-to-earnings-growth ratio of 1.16 and a beta of 1.10. The business has a 50-day moving average price of $155.56 and a 200 day moving average price of $195.01.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. The firm had revenue of $801.70 million during the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. Sell-side analysts expect that Insulet will post 6.45 EPS for the current year.

Insider Transactions at Insulet

In other news, Director Timothy C. Stonesifer acquired 2,790 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the transaction, the director owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.36% of the company’s stock.

Institutional Trading of Insulet

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Larson Financial Group LLC lifted its position in Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Insulet during the 4th quarter worth approximately $26,000. Elyxium Wealth LLC bought a new stake in shares of Insulet during the fourth quarter worth approximately $28,000. DV Equities LLC bought a new stake in shares of Insulet during the fourth quarter worth approximately $28,000. Finally, MV Capital Management Inc. acquired a new position in Insulet in the fourth quarter valued at approximately $29,000.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported second-quarter adjusted earnings of $1.66 per share and revenue of $801.7 million, exceeding analyst estimates of $1.47 and $787.4 million, respectively. Revenue increased 23.5% year over year. Reuters earnings and outlook report
• Positive Sentiment: Management said overall growth remains intact, supported by Omnipod adoption and expansion in the broader insulin-pump market, although the company is resetting expectations for Type 2 customers. Insulet earnings call summary
• Positive Sentiment: Benchmark and Stifel retained “buy” ratings while lowering their price targets to $185 and $180, respectively, implying substantial potential upside from recent levels.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.